EXACT Sciences Corporation (EXAS) support and resistance · rev $2.76B
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
This page maps EXACT Sciences Corporation (EXAS) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
EXAS currently screens at market cap $20.03B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new EXAS 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the EXAS quote page for the session range and the stock page for the full model.
Not investment advice.